Header Logo

Connection

Glen Weiss to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Glen Weiss has written about Lung Neoplasms.
Glen Weiss
Connection Strength
6.660
Lung Neoplasms
  1. Addeo A, Friedlaender A, Banna GL, Weiss GJ. TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol. 2021 Jul; 163:103374.
    View in: PubMed
    Score: 0.444
  2. Addeo A, Banna GL, Weiss GJ. Tumor Mutation Burden-From Hopes to Doubts. JAMA Oncol. 2019 Jul 01; 5(7):934-935.
    View in: PubMed
    Score: 0.389
  3. Weiss GJ, Addeo A. Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. N Engl J Med. 2019 02 28; 380(9):888-889.
    View in: PubMed
    Score: 0.380
  4. Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC). PLoS One. 2016; 11(1):e0144797.
    View in: PubMed
    Score: 0.305
  5. Weiss GJ, Ganeshan B, Miles KA, Campbell DH, Cheung PY, Frank S, Korn RL. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS One. 2014; 9(7):e100244.
    View in: PubMed
    Score: 0.275
  6. Dearing KR, Weiss GJ. Molecular characterization may be of PARAMOUNT importance. J Clin Oncol. 2014 Feb 10; 32(5):481-2.
    View in: PubMed
    Score: 0.266
  7. Weiss GJ. Doubling down with inhibitors of Notch and Hedgehog signaling pathways. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S409-10.
    View in: PubMed
    Score: 0.246
  8. Sheff KW, Hoda MA, Dome B, Hegedus B, Klepetko W, Weiss GJ. The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review. Microrna. 2012; 1(1):40-8.
    View in: PubMed
    Score: 0.231
  9. Raz G, Allen KE, Kingsley C, Cherni I, Arora S, Watanabe A, Lorenzo CD, Edwards V DK, Sridhar S, Hostetter G, Weiss GJ. Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer. Lung Cancer. 2012 May; 76(2):191-6.
    View in: PubMed
    Score: 0.229
  10. Weiss GJ. Targeting the Hedgehog and Notch signaling pathways. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1820-1.
    View in: PubMed
    Score: 0.228
  11. Cherni I, Weiss GJ. miRNAs in lung cancer: large roles for small players. Future Oncol. 2011 Sep; 7(9):1045-55.
    View in: PubMed
    Score: 0.226
  12. Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, Ryken T, Gotway MB, Kim S, Weiss GJ. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer. 2011 Dec 01; 129(11):2621-31.
    View in: PubMed
    Score: 0.219
  13. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol. 2011 Mar; 6(3):482-8.
    View in: PubMed
    Score: 0.218
  14. Ranade AR, Cherba D, Sridhar S, Richardson P, Webb C, Paripati A, Bowles B, Weiss GJ. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol. 2010 Aug; 5(8):1273-8.
    View in: PubMed
    Score: 0.209
  15. Paripati A, Kingsley C, Weiss GJ. Pathway targets to explore in the treatment of small cell and large cell lung cancers. J Thorac Oncol. 2009 Nov; 4(11):1313-21.
    View in: PubMed
    Score: 0.199
  16. Weiss GJ, Kingsley C. Pathway targets to explore in the treatment of non-small cell lung cancer. J Thorac Oncol. 2008 Nov; 3(11):1342-52.
    View in: PubMed
    Score: 0.186
  17. Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
    View in: PubMed
    Score: 0.172
  18. Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2007 Mar; 8(5):335-8.
    View in: PubMed
    Score: 0.165
  19. Weiss GJ, Bunn PA, Camidge DR. From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncology (Williston Park). 2006 Nov; 20(12):1515-24; discussion 1524-5, 1530, 1535.
    View in: PubMed
    Score: 0.162
  20. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA, Kelly K. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Sep 20; 24(27):4405-11.
    View in: PubMed
    Score: 0.160
  21. Dora D, Revisnyei P, Pasic A, Galffy G, Dulka E, Mihucz A, Rosk? B, Szincsak S, Iliuk A, Weiss GJ, Lohinai Z. Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients. Front Immunol. 2025; 16:1543817.
    View in: PubMed
    Score: 0.145
  22. Dora D, Ligeti B, Kovacs T, Revisnyei P, Galffy G, Dulka E, Krizs?n D, Kalcsevszki R, Megyesfalvi Z, Dome B, Weiss GJ, Lohinai Z. Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status. Oncoimmunology. 2023; 12(1):2204746.
    View in: PubMed
    Score: 0.127
  23. Seelbinder B, Lohinai Z, Vazquez-Uribe R, Brunke S, Chen X, Mirhakkak M, Lopez-Escalera S, Dome B, Megyesfalvi Z, Berta J, Galffy G, Dulka E, Wellejus A, Weiss GJ, Bauer M, Hube B, Sommer MOA, Panagiotou G. Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions. Nat Commun. 2023 05 09; 14(1):2673.
    View in: PubMed
    Score: 0.127
  24. Marfil-S?nchez A, Seelbinder B, Ni Y, Varga J, Berta J, Hollosi V, Dome B, Megyesfalvi Z, Dulka E, Galffy G, Weiss GJ, Panagiotou G, Lohinai Z. Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients. PLoS One. 2021; 16(11):e0259898.
    View in: PubMed
    Score: 0.115
  25. Ni Y, Lohinai Z, Heshiki Y, Dome B, Moldvay J, Dulka E, Galffy G, Berta J, Weiss GJ, Sommer MOA, Panagiotou G. Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients. ISME J. 2021 11; 15(11):3207-3220.
    View in: PubMed
    Score: 0.111
  26. Sehgal K, Bulumulle A, Brody H, Gill RR, Macherla S, Qilleri A, McDonald DC, Cherry CR, Shea M, Huberman MS, VanderLaan PA, Weiss GJ, Walker PR, Costa DB, Rangachari D. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 05; 22(3):e379-e389.
    View in: PubMed
    Score: 0.104
  27. Friedlaender A, Drilon A, Weiss GJ, Banna GL, Addeo A. KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. Cancer Treat Rev. 2020 Apr; 85:101978.
    View in: PubMed
    Score: 0.101
  28. Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW. Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer. Int J Cancer. 2018 06 01; 142(11):2355-2362.
    View in: PubMed
    Score: 0.088
  29. Weiss GJ, Lohinai Z. Prophylactic cranial irradiation in small-cell lung cancer. Lancet Oncol. 2017 07; 18(7):e367.
    View in: PubMed
    Score: 0.085
  30. Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017 Jun 27; 117(1):33-40.
    View in: PubMed
    Score: 0.084
  31. Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ. Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs. 2017 10; 35(5):608-615.
    View in: PubMed
    Score: 0.082
  32. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696.
    View in: PubMed
    Score: 0.081
  33. Yamamoto S, Korn RL, Oklu R, Migdal C, Gotway MB, Weiss GJ, Iafrate AJ, Kim DW, Kuo MD. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology. 2014 Aug; 272(2):568-76.
    View in: PubMed
    Score: 0.068
  34. Whitsett TG, Fortin Ensign SP, Dhruv HD, Inge LJ, Kurywchak P, Wolf KK, LoBello J, Kingsley CB, Allen JW, Weiss GJ, Tran NL. FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion. Clin Exp Metastasis. 2014 Aug; 31(6):613-23.
    View in: PubMed
    Score: 0.068
  35. Whitsett TG, Mathews IT, Cardone MH, Lena RJ, Pierceall WE, Bittner M, Sima C, LoBello J, Weiss GJ, Tran NL. Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response. Mol Cancer Res. 2014 Apr; 12(4):550-9.
    View in: PubMed
    Score: 0.067
  36. Kim TY, Jackson S, Xiong Y, Whitsett TG, Lobello JR, Weiss GJ, Tran NL, Bang YJ, Der CJ. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proc Natl Acad Sci U S A. 2013 Oct 15; 110(42):16868-73.
    View in: PubMed
    Score: 0.065
  37. Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, Tran NL, Winkles JA. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol. 2012 Jul; 181(1):111-20.
    View in: PubMed
    Score: 0.059
  38. Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 2012; 7(2):e30820.
    View in: PubMed
    Score: 0.058
  39. Nasser S, Ranade AR, Sridhar S, Haney L, Korn RL, Gotway MB, Weiss GJ, Kim S. Biomarkers associated with metastasis of lung cancer to brain predict patient survival. Int J Data Min Bioinform. 2011; 5(3):287-307.
    View in: PubMed
    Score: 0.054
  40. Heshiki Y, Vazquez-Uribe R, Li J, Ni Y, Quainoo S, Imamovic L, Li J, S?rensen M, Chow BKC, Weiss GJ, Xu A, Sommer MOA, Panagiotou G. Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome. 2020 03 05; 8(1):28.
    View in: PubMed
    Score: 0.025
  41. Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017 Jun 06; 116(12):1505-1512.
    View in: PubMed
    Score: 0.021
  42. Thacker CA, Weiss GJ, Tibes R, Blaydorn L, Downhour M, White E, Baldwin J, Hoff DD, Korn RL. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Med. 2012 Oct; 1(2):230-6.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.